{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:23:49Z","timestamp":1787639029139,"version":"build-2736575974"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"\n Background<\/jats:title>\n Non-alcoholic fatty liver disease (NAFLD) is a major global health issue strongly associated with obesity. Available treatments have significant limitations. The traditional Chinese medicine Huatan Qushi Huoxue (HTQSHX) granules represent a potential alternative therapeutic option. This study evaluates their effects and safety in patients with obesity-associated NAFLD.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This multicenter, randomized, double-blind, placebo-controlled, parallel-group trial recruited 248 patients with obesity-associated NAFLD from three clinical sites. Participants were randomized 1:1 to receive HTQSHX granules or placebo granules for 12\u00a0weeks. The primary outcome was the absolute change in hepatic fat fraction from baseline to week 12, as measured by MRI-proton density fat fraction (MRI-PDFF), which is recommended as a primary endpoint in early-phase NAFLD clinical trials for its precision and objectivity. Secondary outcomes included the proportion of patients achieving \u226530% relative reduction in MRI-PDFF-assessed hepatic fat fraction, serum liver enzyme indicators, glucose and lipid metabolism parameters, non-alcoholic steatohepatitis-related serum biomarkers, anthropometric measures, and serum metabolomics analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 228 participants included in the modified intention-to-treat (mITT) analysis, the median hepatic fat fraction decreased from 16.15% at baseline to 12.12% in the HTQSHX group (median change: 3.27%), and from 15.64% to 14.95% in the placebo group (median change: 0.96%). The between-group difference in absolute change was statistically significant (\u22122.32%; 95% CI, \u22124.50 to \u22120.23;\n P<\/jats:italic>\n = 0.029). The proportion of patients achieving a \u226530% relative reduction in hepatic fat fraction was significantly higher in the HTQSHX group than in the placebo group (41.23% vs. 20.18%;\n P<\/jats:italic>\n &lt; 0.001). The HTQSHX group also showed significantly greater improvements in serum alanine aminotransferase (\n P<\/jats:italic>\n = 0.048), aspartate aminotransferase (\n P<\/jats:italic>\n = 0.033), free fatty acids (\n P<\/jats:italic>\n = 0.026), cytokeratin-18 fragment M30 (\n P<\/jats:italic>\n &lt; 0.001), soluble triggering receptor expressed on myeloid cells 2 (\n P<\/jats:italic>\n &lt; 0.001) and anthropometric parameters (body mass index, waist-to-hip ratio, body fat percentage). Metabolomics analysis of 30 HTQSHX-treated participants revealed that the formula restored multiple phospholipid levels and reduced markers of oxidative stress and mitochondrial dysfunction, with enrichment in fatty acid and sphingolipid metabolism pathways.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n HTQSHX granules may represent a potentially beneficial therapeutic option for obesity-associated NAFLD, with observed effects including significant reduction in hepatic fat fraction and modulation of lipid metabolism and oxidative stress, alongside an acceptable safety profile. These findings warrant further investigation in longer-term studies.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial Registration<\/jats:title>\n \n https:\/\/www.chictr.org.cn\/<\/jats:ext-link>\n , identifier ChiCTR2200060901.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fphar.2026.1899068","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:35:40Z","timestamp":1787636140000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects and safety of Huatan Qushi Huoxue granules on obesity-associated non-alcoholic fatty liver disease: a multicenter, randomized, double-blind, placebo-controlled trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Lihui","family":"Zhang","sequence":"first","affiliation":[{"name":"Hepatology (Gastroenterology) Regional Medical Center, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, Henan, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutong","family":"Liu","sequence":"additional","affiliation":[{"name":"Hepatology (Gastroenterology) Regional Medical Center, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, Henan, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Hepatology (Gastroenterology) Regional Medical Center, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Hepatology (Gastroenterology) Regional Medical Center, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehua","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Shaanxi Provincial Hospital of Traditional Chinese Medicine","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoqing","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Shaanxi Provincial Hospital of Traditional Chinese Medicine","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghao","family":"Liu","sequence":"additional","affiliation":[{"name":"Hepatology (Gastroenterology) Regional Medical Center, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, Henan, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Hepatology (Gastroenterology) Regional Medical Center, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, Henan, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1055\/s-0041-1730927","article-title":"Insights into nonalcoholic fatty-liver disease heterogeneity","volume":"41","author":"Arrese","year":"2021","journal-title":"Semin. Liver Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2022.02.006","article-title":"NAFLD\/NASH","volume":"77","author":"Bugianesi","year":"2022","journal-title":"J. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/hep.0000000000000855","article-title":"Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial","volume":"80","author":"Cheung","year":"2024","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"B5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cld.2023.01.020","article-title":"Roles of radiological tests in clinical trials and the clinical management of nonalcoholic fatty liver disease","volume":"27","author":"Dunn","year":"2023","journal-title":"Clin. Liver Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"955","DOI":"10.14218\/jcth.2024.00311","article-title":"Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (version 2024)","volume":"12","author":"Fan","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0265","DOI":"10.1097\/hc9.0000000000000265","article-title":"sTREM2 is a plasma biomarker for human NASH and promotes hepatocyte lipid accumulation","volume":"7","author":"Kothari","year":"2023","journal-title":"Hepatol. Commun."},{"key":"B10","doi-asserted-by":"publisher","first-page":"157197","DOI":"10.1016\/j.phymed.2025.157197","article-title":"Baicalin ameliorates high-fat diet induced MAFLD by inhibiting ERK\/PPAR\u03b3\/CD36 pathway","volume":"147","author":"Lei","year":"2025","journal-title":"Phytomedicine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/obr.12407","article-title":"Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies","volume":"17","author":"Li","year":"2016","journal-title":"Obes. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ajcnut.2024.07.013","article-title":"Quercetin intervention reduced hepatic fat deposition in patients with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled crossover clinical trial","volume":"120","author":"Li","year":"2024","journal-title":"Am. J. Clin. Nutr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"155398","DOI":"10.1016\/j.phymed.2024.155398","article-title":"Efficacy and safety of Qushi Huayu, a traditional Chinese medicine, in patients with nonalcoholic fatty liver disease in a randomized controlled trial","volume":"130","author":"Liu","year":"2024","journal-title":"Phytomedicine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/hmer.S509778","article-title":"Identification of ferroptosis -Related genes in MAFLD\/MASH and HQHF validation","volume":"17","author":"Liu","year":"2025","journal-title":"Hepat. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/s2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3760\/cma.j.issn.1007-3418.2018.03.008","article-title":"Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update","volume":"26","year":"2018","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/apt.70376","article-title":"Exploration of multiple non-invasive tests for assessing response to treatment in a semaglutide phase 2b trial in patients with MASH","volume":"63","author":"Nitze","year":"2026","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3390\/antiox13091026","article-title":"Tanshinone IIA inhibits the endoplasmic reticulum stress-induced unfolded protein response by activating the PPAR\u03b1\/FGF21 axis to ameliorate nonalcoholic steatohepatitis","volume":"13","author":"Pi","year":"2024","journal-title":"Antioxidants (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/s0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100058","DOI":"10.1016\/j.pharmr.2025.100058","article-title":"Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease","volume":"77","author":"Rodriguez","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e1000251","DOI":"10.1371\/journal.pmed.1000251","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"7","author":"Schulz","year":"2010","journal-title":"PLoS Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.14309\/ajg.0000000000002098","article-title":"Exercise training is associated with treatment response in liver fat content by magnetic resonance imaging independent of clinically significant body weight loss in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"118","author":"Stine","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41574-021-00584-0","article-title":"Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD","volume":"18","author":"Tamaki","year":"","journal-title":"Nat. Rev. Endocrinol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/gutjnl-2021-324264","article-title":"Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease","volume":"71","author":"Tamaki","year":"","journal-title":"Gut"},{"key":"B27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s2468-1253(24)00049-9","article-title":"Resmetirom for NASH: balancing promise and prudence","volume":"9","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jama.2024.2600","article-title":"Tirzepatide for maintenance of weight reduction in adults with obesity","volume":"331","author":"Xiao","year":"2024","journal-title":"Jama"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7884","DOI":"10.1021\/acs.jafc.1c02257","article-title":"Oleanolic acid targets the gut-liver axis to alleviate metabolic disorders and hepatic steatosis","volume":"69","author":"Xue","year":"2021","journal-title":"J. Agric. Food Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/hep.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"","journal-title":"Hepatology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1080\/10408398.2022.2138257","article-title":"Nutritional activities of luteolin in obesity and associated metabolic diseases: an eye on adipose tissues","volume":"64","author":"Zhang","year":"2024","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/cvr\/cvaf096","article-title":"Fetuin-A increases thrombosis risk in non-alcoholic fatty liver disease by binding to TLR-4 on platelets","volume":"121","author":"Zhang","year":"2025","journal-title":"Cardiovasc Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.13288\/j.11-2166\/r.2012.12.002","article-title":"Clinical observation of modified Huatan Lishi Huoxue formula in the treatment of 96 patients with nonalcoholic steatohepatitis","volume":"53","author":"Zhao","year":"2012","journal-title":"J. Traditional Chin. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13020-023-00724-w","article-title":"Electro-acupuncture reduced steatosis on MRI-PDFF in patients with non-alcoholic steatohepatitis: a randomized controlled pilot clinical trial","volume":"18","author":"Zhao","year":"2023","journal-title":"Chin. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1899068\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:35:44Z","timestamp":1787636144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1899068\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":36,"alternative-id":["10.3389\/fphar.2026.1899068"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1899068","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1899068"}}